monrd0002
Medals oligonucleic drug ID monrd0002
ATC Classification -
Product Name aganirsen
Synonims GS101
Country France
Company Les Laboratoires CTRS
phase II/III
Type Antisense
Adaptation Diseases inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection
Target Molecule insulin receptor substrate-1 (IRS1)
Remarks Aganirsen is an antisense oligonucleotide ophthalmic solution that inhibits the function of insulin receptor IRS1.
In Phase II study, inhibition of corneal neovascularization was confirmed.
Double mask, randomization, placebo-controlled Phase III trials at multiple locations examined clinical benefits for vision, QoL, and the need for transplantation.
The trial showed significant inhibition of corneal angiogenesis in patients with keratitis, a significant reduction in transplantation need in viral keratitis and central angiogenic patients. The safety of topical application was also confirmed.
Nucleic Acid Sequence -
Source https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005388-33/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005015-29/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005015-29/results,
http://www.ncbi.nlm.nih.gov/pubmed/19643487,
https://www.ncbi.nlm.nih.gov/pubmed/24811963,
http://www.genesignal.com/GS-101_Aganirsen_Clinical_Tr.32.0.html
DrugBank -
TargetProtein - UniProt P35568
TargetProtein - PDB 1IRS, 1QQG